The chart shows that coronary heart disease and stroke are responsible for 27% of total deaths. Both belong to cardiovascular disease. The most common cancer, lung cancer causes 3% of deaths.
The main risk factors for cardiovascular disease are diabetes, hypertension and obesity. It can be assumed that the importance of this disease will be even higher going forward.
But investments in cardiovascular drug development are much lower than in other therapeutic areas. One explanation is the high cost of conducting large cardiovascular trials. The need for successful prevention strategies, access to existing therapies and the development of new innovative drugs offer attractive investment opportunities.
What mattered this month in healthcare? The readout of the SELECT study was the single biggest healthcare event of the month. The results may open the door to wide reimbursement for GLP-1 weight-loss drugs. This led to an overreaction with significant price movements amongst many companies as markets just made blanket assumptions of a healthier, thinner world. Find out more in our monthly healthcare newsletter.
Remarkable Strides in Breast Cancer Survival: A Look at the Last Few Decades 🎗️📈 Intersted in knowing more? Check out Maria Specogna’s latest chart of the month video!
What mattered this month in healthcare? Second quarter earnings season kicked off to a strong start, with earnings overall better than estimates. However, positioning matters, and strong numbers were not always enough if expectations were high. Find out more in our monthly healthcare newsletter.